Nuclera launches gpcr-focused nanodisc panel to streamline membrane protein production. * Enables expression of active GPCRs in 48 hours * Panel supports screening to scale-up on eProtein Discovery Cambridge, UK, and Boston MA, USA, 30 March 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). Building on the eProtein Discovery(TM) membrane protein workflow capabilities[1], the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of challenging therapeutic targets, GPCRs, producing active proteins in 48 hours. Nuclera's nanodisc panel includes a GPCR screen kit and scale-up reagents, including 8 nanodisc combinations, comprised of 2 membrane scaffold proteins (MSPs), and 4 lipid compositions. Allowing researchers to rapidly and cost-effectively express active GPCRs, the nanodisc panel minimizes variability associated with traditional approaches to membrane protein production. The preassembled nanodiscs target the specific charge, fluidity and/or cholesterol requirements for GPCR activity and yield. Despite one third of FDA-approved drugs acting on GPCRs[2], obtaining purified, stable, functional GPCRs remains a critical bottleneck in pharmacology and drug discovery. Traditionally, cell-based detergent micelles are used to solubilize membrane proteins, but often lead to proteins adopting non-native conformations. Nanodiscs provide a soluble membrane bilayer allowing the study of membrane proteins and their interactions under native-like conditions better maintaining structural integrity and in vivo functionality compared to detergent-based approaches. Integrating Nuclera's pre-assembled nanodiscs directly into eProtein Discovery's cell-free protein synthesis (CFPS) approach enables co-translational insertion of the nascent protein. This delivers high yields of soluble, active membrane protein with improved stability for downstream applications and streamlines drug discovery workflows from screening to characterization. Dr Audrey Dubourg, Product Manager, Nuclera, said: "Since releasing our membrane protein workflow in 2025, we have identified a huge potential in the market to support GPCR protein scientists. Our eProtein Discovery(TM) nanodisc panel empowers researchers to explore physiologically relevant environments validated for solubility, insertion and stabilization of membrane proteins. Compared to traditional approaches, these are capable of increasing protein yield whilst maintaining functionality, creating a fast-track route to purified, active GPCRs." Dr Michael Chen, CEO and co-founder, Nuclera, commented: "The release of our GPCR nanodisc panel addresses the pressure scientists face to rapidly produce functional membrane proteins. Integrated with eProtein Discovery, this capability equips researchers with a powerful approach to increase success rates in expressing active GPCRs."

Nuclera and TRIMTECH Therapeutics success at the One Nucleus Awards 2026. 29 Mar 2026 Many congratulations to all of the winners and finalists, including portfolio compnaies Nuclera and TRIMTECH Therapeutics The winners of the One Nucleus Awards 2026 were announced at an awards ceremony in London on 29 March. The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders. Best Therapeutic R&D Programme of the Year | Winner: Resolution Therapeutics | Finalists: Serenatis Bio, TRIMTECH Therapeutics Best Use of Emerging Technology of the Year | Winner: Nuclera | Finalists: Ignota Labs, Constructive Bio

Portfolio company Nuclera has been ranked in the top 10 of this year's Sifted 100: UK & Ireland leaderboard. Sifted 18 Mar 2026 Rising an impressive 37 places from last year to secure 10th position, Nuclera recorded the largest year-on-year climb across the entire ranking. This recognition underscores Nuclera's growing impact as one of the leading companies driving economic growth and innovation in an increasingly competitive landscape. Sifted 100: UK & Ireland (2026) Welcome to the third annual Sifted 100: UK & Ireland Leaderboard, which ranks the region's 100 fastest-growing startups and scaleups by revenue growth over the past three financial years. Together, these 100 companies have raised £18.4bn in funding, generated £2.6bn in revenue over the last three years and now employ around 10,750 people across the UK and Ireland. Notably, £1.7bn of that revenue was generated in the most recent year alone, underscoring just how quickly these startups are scaling. To be eligible, startups had to be private, independent and headquartered in the UK or Ireland, with the majority of revenue generated from proprietary technology. Companies must have been founded in or after 2010, and have at least three years of revenue data (from 2022-2024, 2023-2025 or 2024-2026), covering accounting periods of at least 26 weeks. Revenue had to be at least £42k in the base year and £420k in the most recent year. Companies were required to submit signed documentation to verify any financial data not publicly available. Some opted to keep parts of this information confidential. Read the accompanying research report, featuring interviews with 20+ founders and investors, as well its ranking of the 100+ investors and lenders with at least two companies on the leaderboard.